Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

|<

<

11

12

13

14

15

16

17

18

19

20

21

22

23

24

>

>|

Found 96 Matches

Sulfadoxine

Brand Name(s) include: Fansidar

Disease: Malaria

Drug Class: Sulfonamide

Date Updated: March 2021

The model at-a-glance

  Absorption Model

  • First-Order

  Volume of Distribution

  • Minimal PBPK (User input Vss)

  Route of Elimination

  • Renal clearance (90%); non-specific hepatic metabolism (10%)

  Perpetrator DDI

  • None

  Validation

  • Four clinical studies describing single and multiple dose exposure of sulfadoxine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 100% of the studies were within 2-fold and 75% were within 1.5-fold. 

  Limitations

  • In the absence of adequate data on the metabolism and excretion of sulfadoxine, it was assumed that 90% was cleared renally and 10% was metabolized by the liver.

  Updates in V19

  • Updated in vitro­ data
    • LogP: 4.22 -> 0.54

 

this is a test

Tramadol_V14R1_AstraZeneca_20200427
Tramadol adult compound file for pediatric prediction. The following parameters need to be updated, as compared to Table 2 in the manuscript: CYP2D6 0.7, CYP3A4 0.035, CYP2B6 0.1, CLr 6.6 L/hr
Morphine&Morphine-3-Glucuronide_V18R1_UniversityOfNorthCarolina_20201005
The submitted workspace file is for Morphine and Morphine-3-glucuronide compound files, with a full PBPK distribution model, ADAM and permeability-limited liver. The model also includes enterohepatic recycling and cleavage of the glucuronide in the gut lumen. The Sim-Healthy Volunteers population library was modified with regards to the relative enzyme abundance of luminal deglucuronidation. The setting in the workspace reflects the trial design from Stuart-Harris et al., 2000. Stuart-Harris R, Joel SP, McDonald P, Currow D, Slevin ML. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine. Br J Clin Pharmacol 49 207-214. (2000)

|<

<

11

12

13

14

15

16

17

18

19

20

21

22

23

24

>

>|